semaglutide and cardiovascular disease Outcomes in Obesity without Diabetes VisualAbstract: Semaglutide and Cardiovascular Outcomes
Description
Outlet in Room:20Amp 230V Outlet
The widespread prevalence of diabetes, caused by impaired insulin secretion and insulin resistance, is now a worldwide health problem
Mounjaro(tirzepatide) and Trulicity (dulaglutide) are both FDA-approved GLP-1 receptor agonists made by Eli Lilly and are used to treat type 2 diabetes.
Further studies are required to validate these observations
Eight studies comprised of 715 children and adolescents were included
